

Dr Annunziata (Nancy) Dattola
Dr Annunziata (Nancy) Dattola is Researcher at the Department of Dermatology, University of La Sapienza in Rome, Italy.
Her main field of interest is the diagnosis and treatment of inflammatory skin diseases. In 2013, Dr Dattola completed a 2-year fellowship at the Laboratory for Investigative Dermatology at the Rockefeller University, New York, NY. During her fellowship, she focused on psoriasis, metabolic syndrome and imaging such as positron emission tomography (PET)/computerised tomography (CT), sono-elastography, and CT angiography, in the diagnosis of patients with psoriasis. In January 2021, she completed her PhD in Biochemistry and Molecular Biology with a thesis entitled: “Results of two different biological treatments in patients with PsO and PsA, and detection of early arthritis”.
Dr Dattola’s current research includes projects on biological agents for the treatment of psoriasis, laser and cosmetology. She is also involved in numerous phase III clinical trials and is author of many papers on these topics. She completed 3 years of research at the University of Rome Tor Vergata from 2018 to 2021.
Dr Dattola is a member of the “Italian task force” for women with psoriasis, member of the Italian Society of Dermatology and Venereology (SIDeMaST), member of the European Academy of Dermatology and Venereology (EADV) and member of the local organising committee for the World Congress of Dermatology 2019 Milan, Italy.
Prof. Falk Bechara covers the different surgical options for HS, and experienced nurses from his team discuss the importance of wound care
Prof. Thrasyvoulos Tzellos gives an overview of HS treatment options. Dr Barry McGrath and Prof. Gregor Jemec provide their views on the HCP-patient relationship
Prof. Christos Zouboulis and Dr Axel Villani kick-off the webinar series by explaining the fundamentals of the HS disease story and pathophysiology
Accompany Dr William Tillett and Dr Fabian Proft as they explore the approaches and challenges of managing D2T patients with PsA.
Achieving MDA or DAPSA treatment targets improves quality of life for patients with PsA.1–4 Explore the characteristics of patients who report treatment success...
ASDAS and BASDAI are commonly used in clinical practice.1,2 However, discover recent studies demonstrating that a high proportion of real-world patients do not...